Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment - Contacts and Locations

Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

This study is currently recruiting participants.
Information provided by National Institute of Mental Health (NIMH)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00352885

Contacts


Contact: Erica C. Bruce, MPH	404-712-9614	ecbruce@emory.edu

Contact: Carol Hill, RN	404-778-4907	carol.hill@emoryhealthcare.org

Locations


United States, Georgia
	Winship Cancer Institute	Recruiting
	Atlanta, Georgia, United States, 30322

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators


Principal Investigator:	Dominique L. Musselman, MD,MS	Emory University

Study Chair:	David Lawson, MD	Emory University

Study Chair:	Andrew Miller, MD	Emory University